| Zacks Company Profile for Astellas Pharma Inc. (ALPMY : OTC) |
|
|
| |
| • Company Description |
| Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Number of Employees: 14,754 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $9.41 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 122,390 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 0.23 |
| 52 Week High: $13.14 |
| 52 Week Low: $8.37 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-3.88% |
-7.48% |
| 12 Week |
0.64% |
-15.35% |
| Year To Date |
-2.59% |
-8.77% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2-5-1 Nihonbashi-Honcho Chuo-Ku
-
Tokyo,M0 103-8411
JPN |
ph: 813-3244-3000
fax: - |
None |
http://www.astellas.com |
|
|
| |
| • General Corporate Information |
Officers
Naoki Okamura - Chief Executive Officer and President
Kenji Yasukawa - Chairman of the Board
Katsuyoshi Sugita - Executive Vice President
Takashi Tanaka - Outside Director
Tomoko Aramaki - Outside Director
|
|
Peer Information
Astellas Pharma Inc. (GSAC)
Astellas Pharma Inc. (CASI)
Astellas Pharma Inc. (ALCD.)
Astellas Pharma Inc. (OMNN)
Astellas Pharma Inc. (CGPI.)
Astellas Pharma Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 04623U102
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 4.00 (1.25:1)
Beta: 0.23
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 3.70% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.35 |
| Current Fiscal Year EPS Consensus Estimate: $0.86 |
Payout Ratio: 0.37 |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: -0.11 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/07/25 |
|
|
|
| |
